Partners

Industrial & Academic Collaborations


 


Roche – Phase I trial BDB001 + atezolizumab (anti-PD-L1)

 

Merck (MSD) – Phase I trial BDB001 + pembrolizumab (anti-PD-1)

 


Bergonie